Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dark Halo a New Biomarker in Macular Neovascularization: a Comparative Study Between ICGA and OCTA

NCT05108285 is registered in ClinicalTrials.gov with Federico II University as lead sponsor.

NCT NCT05108285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05108285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dark Halo a New Biomarker in Macular Neovascularization: a Comparative Study Between ICGA and OCTA
Lead sponsor
Federico II University
Phase
Observational
Overall status
Completed
Start date
January 1, 2018
Completion date
December 15, 2020
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

macular neovascularisation